Article Text

PDF
Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration
  1. C Calvo-González1,
  2. J Reche-Frutos1,
  3. J Donate-López1,
  4. J García-Feijoó1,
  5. M Leila2,
  6. C Fernández-Pérez1,
  7. J Garcia-Sánchez1
  1. 1
    Hospital Universitario Clínico San Carlos, Madrid, Spain
  2. 2
    Magrabi Eye Hospital, Egypt
  1. Cristina Calvo-González, C/Profesor Martín Lagos s/n 28040, Madrid, Spain; calvo_glez{at}yahoo.es

Abstract

Aims: This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen®) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients.

Results: Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm2 to 2.7 mm2. There was a significant increase in the greatest linear dimension (GLD) from 1280.3 μm to 2065.7 μm at the 24-week follow-up.

Conclusion: Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh, Editors-in-Chief